Blood Biomarkers Beyond Cancer: NfL, pTau217, and Neurological Diagnostics | Diagnostics Market Intelligence

Description

List of Tables

Neurology is following oncology into the blood. The same analytical sensitivity that made circulating tumor DNA measurable now makes phosphorylated tau, neurofilament light chain, and GFAP readable from a plasma draw, and the timing is not accidental: the first disease-modifying Alzheimer's therapies reached the market - including in Japan - with eligibility rules that demand biological confirmation of amyloid pathology. PET scans and lumbar punctures can provide it, but a health system facing millions of potential candidates cannot run on imaging slots and spinal taps. The blood test is the missing capacity layer, and the diagnostics industry knows it.

Japan sits in a distinctive position in this race. Fujirebio's Lumipulse platform secured the first FDA clearance for a blood-based Alzheimer's ratio test in 2025 and followed with a CE-marked neurofilament light assay in 2026 - Japanese IVD engineering leading a global category. Sysmex and Fujirebio moved in 2026 to combine commercialization strength in Japan. Roche's Elecsys neurology pipeline and Quanterix's ultrasensitive Simoa assays define the competitive frontier. Yet inside Japan itself, the reimbursement machinery has not caught up: CSF and PET have established payment pathways, while the blood tests that could relieve both sit in a pricing gap, with NHI coverage undecided and the dementia therapy rollout constrained by diagnostic capacity at every step.

This report maps the emerging category from analyte to payment. It explains the biomarker biology and assay technologies in operational terms, profiles each platform and its regulatory positions across the FDA, CE, and PMDA systems, and examines the clinical integration questions: where blood tests sit relative to PET and CSF, how results should gate therapy eligibility, and how primary care and specialist roles divide. Beyond Alzheimer's, dedicated chapters cover neurofilament light in multiple sclerosis and ALS, and the wider neurodegeneration panel opportunity. Reimbursement analysis addresses the Japanese gap directly, with the US and European coverage experiments as reference.

The report serves IVD strategy and business-development teams, neurology pharmaceutical companies planning therapy launches, investors assessing the neuro-diagnostics category, and health-system planners confronting dementia diagnostic capacity.

Scope and Coverage: The report covers blood-based neurological biomarkers - pTau217, pTau181, NfL, GFAP, and amyloid ratios - in Japan: technology, platforms, regulatory status, clinical integration, and reimbursement, with applications across Alzheimer's and other neurological diseases. Comparative coverage includes the United States and Europe.

Report Highlights:

Analyte and assay technology landscape: pTau217, pTau181, NfL, GFAP, and amyloid ratios
Platform profiles: Fujirebio Lumipulse, Roche Elecsys, Quanterix Simoa, and C2N mass spectrometry
Regulatory milestones including the 2025 FDA clearance and 2026 CE marking
The Sysmex-Fujirebio commercialization collaboration and its market implications
Clinical pathway design: blood tests relative to PET and CSF in therapy eligibility
Japan's reimbursement gap and the coverage pathways under discussion

Product Code: JPH-057

Table of Content

1. Executive Summary

2. Blood Biomarkers Beyond Cancer: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Fujirebio (JP) - Lumipulse pTau217/B-amyloid 1-42 ratio (FDA clearance 2025) and CE-marked NfL assay (2026). Roche (CH) - Elecsys pTau181 (FDA clearance 2025) and Elecsys pTau217/AB42 ratio (CE marked). Quanterix (US) - Simoa ultrasensitive pTau217, pTau181, NfL, and GFAP assays. C2N Diagnostics (US) - PrecivityAD and PrecivityAD2 blood tests for amyloid pathology. Sysmex (JP) - HISCL B-amyloid 1-42/1-40 approved in Japan (2023); exclusive Japan sales collaboration with Fujirebio (2026). Shimadzu (JP) - mass-spectrometry amyloid blood assay research heritage. Beckman Coulter (US) - Access pTau217 and neuro markers in development. Abbott (US) - Alinity neuro-biomarker assay development program. Alamar Biosciences (US) - NULISA ultrasensitive proteomics with neuro panels. ADx NeuroSciences (BE) - Fujirebio subsidiary originating the pTau217 assay antibodies. Eisai (JP) - Leqembi sponsor creating Japanese demand for amyloid-confirmation testing. Eli Lilly (US) - Kisunla sponsor with the same biomarker-testing dependency in Japan.

Product Code: JPH-057

List of Tables

Table 1. Blood-based neurological biomarkers: clinical rationale
Table 2. Alzheimer's diagnostic pathway: PET, CSF, and blood testing
Table 3. Disease-modifying therapy eligibility and diagnostic gating
Table 4. Leqembi and Kisunla diagnostic requirements in Japan
Table 5. Primary care versus specialist roles in dementia diagnosis
Table 6. Neurology applications of blood biomarkers beyond Alzheimer's
Table 7. Amyloid confirmation testing capacity in Japan
Table 8. pTau217 biology and assay landscape
Table 9. pTau181 and pTau231 comparative roles
Table 10. Neurofilament light chain applications across neurological disease
Table 11. GFAP and multiplex neurodegeneration panels
Table 12. Plasma amyloid 42/40 ratio assays
Table 13. Fujirebio Lumipulse pTau217/amyloid ratio FDA clearance (2025)
Table 14. Fujirebio CE-marked NfL assay (2026)
Table 15. Roche Elecsys pTau181 and pTau217/amyloid programs
Table 16. Quanterix Simoa neurology assay menu
Table 17. C2N PrecivityAD mass spectrometry approach
Table 18. Sysmex-Fujirebio sales collaboration structure (2026)
Table 19. Abbott, Beckman, and Siemens neuro-biomarker programs
Table 20. Immunoassay, mass spectrometry, and Simoa performance frameworks
Table 21. Pre-analytical requirements for plasma neuro markers
Table 22. Reference range and cutoff establishment
Table 23. Two-cutoff and intermediate-zone result strategies
Table 24. Standardization and commutability initiatives
Table 25. FDA clearance pathway for blood-based Alzheimer's tests
Table 26. CE marking under IVDR for neurology assays
Table 27. PMDA review status for neuro-biomarker assays
Table 28. NHI reimbursement gap for blood-based neuro diagnostics
Table 29. Reimbursement precedent: CSF biomarker testing in Japan
Table 30. Reimbursement precedent: amyloid PET coverage decisions in Japan
Table 31. Reimbursement pathway options for blood tests
Table 32. US coverage frameworks for blood-based Alzheimer's tests
Table 33. European coverage and procurement experiments
Table 34. Health economics evidence requirements for coverage
Table 35. Optimal Use Guidelines diagnostic workflow for DMTs in Japan
Table 36. Dementia specialist versus primary care testing models
Table 37. Result interpretation and counseling frameworks
Table 38. Integration with MRI and cognitive assessment
Table 39. Monitoring applications during DMT treatment
Table 40. ARIA management and biomarker roles
Table 41. Clinical trial use of blood biomarkers in neurology
Table 42. Research-use versus clinical-use boundaries
Table 43. NfL in multiple sclerosis management
Table 44. NfL in ALS trial and clinical applications
Table 45. Biomarkers in Parkinson's disease and synucleinopathies
Table 46. Traumatic brain injury applications of GFAP and UCH-L1
Table 47. Japanese neurology and dementia society positions
Table 48. IVD competitive landscape in neuro biomarkers
Table 49. Pharmaceutical-diagnostic partnership activity in neurology
Table 50. Report methodology and evidence sources

List of Figures

Figure 1. Blood biomarker clinical rationale schematic
Figure 2. Alzheimer's diagnostic pathway comparison: PET, CSF, blood
Figure 3. DMT eligibility gating flow
Figure 4. Leqembi and Kisunla diagnostic requirement map
Figure 5. Primary-specialist role division in dementia diagnosis
Figure 6. Beyond-Alzheimer's application map
Figure 7. Amyloid confirmation capacity structure
Figure 8. pTau217 assay landscape map
Figure 9. pTau isoform role comparison
Figure 10. NfL application map across neurology
Figure 11. GFAP panel architecture
Figure 12. Amyloid ratio assay workflow
Figure 13. Lumipulse FDA clearance pathway schematic
Figure 14. Fujirebio NfL CE marking pathway
Figure 15. Elecsys neuro pipeline map
Figure 16. Simoa neurology menu map
Figure 17. C2N mass spectrometry workflow
Figure 18. Sysmex-Fujirebio collaboration structure
Figure 19. Major IVD neuro program map
Figure 20. Platform performance framework comparison
Figure 21. Pre-analytical requirement map
Figure 22. Cutoff establishment framework
Figure 23. Two-cutoff result strategy schematic
Figure 24. Standardization initiative map
Figure 25. FDA clearance pathway flow
Figure 26. IVDR pathway for neuro assays
Figure 27. PMDA review status map
Figure 28. NHI reimbursement gap schematic
Figure 29. CSF reimbursement precedent timeline
Figure 30. Amyloid PET coverage decision timeline
Figure 31. Blood test reimbursement pathway options
Figure 32. US coverage framework map
Figure 33. European coverage experiment map
Figure 34. Health economics evidence framework
Figure 35. Optimal Use Guidelines workflow in Japan
Figure 36. Specialist versus primary testing model map
Figure 37. Result interpretation and counseling flow
Figure 38. MRI and cognitive assessment integration map
Figure 39. Treatment monitoring biomarker pathway
Figure 40. ARIA management biomarker role map
Figure 41. Trial use of blood biomarkers map
Figure 42. Research versus clinical use boundary map
Figure 43. NfL in MS management pathway
Figure 44. NfL in ALS application map
Figure 45. Synucleinopathy biomarker map
Figure 46. TBI biomarker application map
Figure 47. Society position map in Japan
Figure 48. Neuro-biomarker competitive landscape map
Figure 49. Pharma-diagnostic partnership map
Figure 50. Report methodology schematic

Blood Biomarkers Beyond Cancer: NfL, pTau217, and Neurological Diagnostics | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Blood Biomarkers Beyond Cancer: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures